Top Page
Genus plc
(LSE:GNS)
Genus plc (GNS) vs. iShares MSCI United Kingdom ETF (EWC)
Genus plc Business Overview & Revenue Model
Genus plc Earnings Call Summary
Genus plc Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 672.00M | 672.80M | 668.80M | 689.70M | 593.40M | 574.30M |
| Gross Profit | 672.50M | 672.80M | 178.70M | 239.30M | 226.00M | 232.20M |
| EBITDA | 111.10M | 93.70M | 73.70M | 87.50M | 79.80M | 82.30M |
| Net Income | 47.50M | 19.30M | 7.90M | 33.30M | 40.90M | 47.30M |
Balance Sheet | ||||||
| Total Assets | 921.30M | 899.00M | 1.03B | 1.01B | 1.02B | 851.00M |
| Cash, Cash Equivalents and Short-Term Investments | 43.40M | 48.00M | 42.50M | 36.30M | 38.80M | 46.00M |
| Total Debt | 277.70M | 265.90M | 291.20M | 232.10M | 223.80M | 151.60M |
| Total Liabilities | 417.40M | 423.00M | 485.00M | 440.30M | 445.80M | 354.40M |
| Stockholders Equity | 504.00M | 475.60M | 548.20M | 569.40M | 578.50M | 498.10M |
Cash Flow | ||||||
| Free Cash Flow | 57.20M | 48.60M | 5.10M | 15.20M | -7.80M | 38.80M |
| Operating Cash Flow | 70.70M | 67.20M | 29.80M | 50.40M | 34.30M | 67.50M |
| Investing Cash Flow | -18.50M | -13.80M | -19.30M | -30.90M | -67.20M | -46.70M |
| Financing Cash Flow | -48.90M | -46.60M | -2.80M | -18.20M | 21.90M | -14.20M |
Genus plc Technical Analysis
Genus plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £75.76M | 18.93 | 64.40% | 8.33% | -3.61% | -6.35% | |
69 Neutral | £1.86B | 14.39 | 3.77% | 1.25% | 0.60% | 143.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £1.09B | -8.50 | -26.01% | ― | 22.03% | 20.01% | |
45 Neutral | £10.73M | -0.25 | -407.49% | ― | 72.17% | 79.03% | |
44 Neutral | £17.50M | -9.67 | -164.37% | ― | -11.43% | 23.40% | |
41 Neutral | £83.62M | -4.89 | -209.34% | ― | 198.49% | -26.66% |
Genus plc Corporate Events
Genus plc has disclosed that non-executive director Celia Baxter bought 1,728 ordinary shares in the company on 27 February 2026 on the London Stock Exchange at an average price of £28.92865 per share. The purchase, classified as a director dealing under Market Abuse Regulation requirements, marginally increases insider ownership and may be viewed by investors as a signal of confidence in the company’s prospects.
The transaction was notified as an initial disclosure under Article 19 of the Market Abuse Regulation, which mandates prompt reporting of share dealings by persons discharging managerial responsibilities. While the stake acquired is relatively small in absolute terms, such purchases are often monitored by shareholders as indicators of alignment between board members and investor interests, as well as potential sentiment about future performance.
The most recent analyst rating on (GB:GNS) stock is a Hold with a £3110.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Genus reported record first-half profits for the six months to 31 December 2025, as adjusted operating profit jumped on strong performance at its porcine unit PIC, a milestone payment from Chinese partner Beijing Capital Agribusiness and ongoing cost and efficiency gains from its Value Acceleration Programme in bovine unit ABS. Revenue was flat at £335.6m but adjusted profit before tax rose 57%, adjusted EPS climbed 53%, free cash flow remained solid and leverage fell, prompting a higher interim dividend and underlining the benefits of royalty-led growth, lower input costs and disciplined cash generation.
Strategically, the group advanced its long-term positioning with the formation of a Chinese porcine joint venture that will deconsolidate PIC China and is expected to bring in about £100m in fiscal Q4, while Canada’s approval of its PRRS-resistant pig gene edit marked a key step toward commercialising this flagship innovation in North America. Management said second-half trading momentum remains positive and, after factoring in the PIC China deconsolidation and broadly neutral FX, full-year adjusted profit guidance is in line with market expectations, reinforcing confidence in the company’s growth trajectory despite softer ABS revenue and ongoing regulatory and trade challenges in China.
The most recent analyst rating on (GB:GNS) stock is a Hold with a £3455.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Genus plc has released its latest six-monthly block listing return covering the period from 1 August 2025 to 31 January 2026, detailing movements in shares available under its employee and executive share schemes. The company reported that the 2004 Executive Share Option Plan and the International Share Incentive Plan saw no new shares allotted during the period, leaving balances of 13,897 and 79,671 unallotted securities respectively, while 840 shares were issued under the 2021 Share Incentive Plan, reducing its unallotted balance to 69,927; this indicates modest utilisation of employee share plans and stable potential future dilution for existing shareholders.
The most recent analyst rating on (GB:GNS) stock is a Hold with a £3460.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Genus plc has confirmed that as of 31 January 2026 its issued share capital comprises 66,538,294 ordinary shares of 10 pence each, all carrying identical voting rights and with no shares held in treasury. This clarification of the company’s total voting rights provides a clear denominator for shareholders and investors to calculate and disclose their holdings under the FCA’s Disclosure Guidance and Transparency Rules, supporting regulatory compliance and transparency in Genus’s ownership structure.
The most recent analyst rating on (GB:GNS) stock is a Hold with a £3460.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Genus plc has completed the formation of its Chinese porcine joint venture with Beijing Capital Agribusiness, a move it sees as the optimal platform to accelerate the growth of its PIC China business. The deal will bring Genus a gross cash payment of US$160m, on top of a previously recognised US$7.5m milestone payment, and will result in PIC China being deconsolidated from the group’s accounts, signalling a shift in how the business is reported and potentially improving financial flexibility while maintaining significant exposure to the strategically important Chinese pork market.
The most recent analyst rating on (GB:GNS) stock is a Hold with a £3460.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Genus plc, a global leader in animal genetics focused on dairy, beef and pork sectors, operates through its ABS and PIC brands to deliver advanced breeding products and services worldwide from its headquarters in Basingstoke. The company has completed the formation of its Chinese porcine joint venture with Beijing Capital Agribusiness, triggering a gross cash payment of US$160m and an earlier US$7.5m milestone, and leading to the deconsolidation of its 49%-owned PIC China business from the group accounts, a structural shift expected to reshape its financial reporting and potentially accelerate the growth of its Chinese pork genetics operations.
The most recent analyst rating on (GB:GNS) stock is a Hold with a £3460.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Genus plc has secured regulatory approval in Canada for the use of its gene-edited PRRS Resistant Pig (PRP), marking a key milestone toward commercialising the technology in North America after years of collaboration with Canadian authorities. The company views this clearance as a significant step but notes that further approvals in major North American export markets, particularly Mexico and Japan, as well as in other jurisdictions including China, will be critical to full rollout, especially given the heavy economic and animal health burden of PRRS, which costs U.S. producers an estimated $1.2 billion annually and has been linked to sharply higher antibiotic use.
The most recent analyst rating on (GB:GNS) stock is a Hold with a £2954.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.
Genus reported a stronger-than-expected performance for the first half of its 2026 financial year, with adjusted profit before tax (excluding a milestone payment) anticipated at about £50m, ahead of internal expectations, and around £55.6m including the milestone. Driven by robust trading at its PIC pork genetics unit and in-line performance at ABS, the board now forecasts full-year adjusted profit before tax (excluding the milestone) to come in moderately above the top end of current market expectations, signalling positive momentum in core operations. The group also confirmed that China’s SASAC has approved the formation of its porcine joint venture in China, triggering a final $7.5m milestone payment from partner BCA, with completion and cash receipt expected in the fiscal third quarter, underscoring Genus’s strategic push into the Chinese pork market and reinforcing its growth prospects in a key global protein sector.
The most recent analyst rating on (GB:GNS) stock is a Hold with a £2836.00 price target. To see the full list of analyst forecasts on Genus plc stock, see the GB:GNS Stock Forecast page.